{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T06:11:43Z","timestamp":1772604703205,"version":"3.50.1"},"reference-count":21,"publisher":"Impact Journals, LLC","issue":"22","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2018,3,23]]},"DOI":"10.18632\/oncotarget.23806","type":"journal-article","created":{"date-parts":[[2018,1,2]],"date-time":"2018-01-02T07:47:19Z","timestamp":1514879239000},"page":"16213-16219","source":"Crossref","is-referenced-by-count":9,"title":["An open label, single-armed, exploratory study of apatinib (a novel VEGFR-2 tyrosine kinase inhibitor) in patients with relapsed or refractory non-Hodgkin lymphoma"],"prefix":"10.18632","volume":"9","author":[{"given":"Ling","family":"Li","sequence":"first","affiliation":[{"name":"Department of Oncology, Lymphoma Diagnosis and Treatment Center of Henan Province, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sa","family":"Xiao","sequence":"additional","affiliation":[{"name":"Department of Oncology, Lymphoma Diagnosis and Treatment Center of Henan Province, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Lymphoma Diagnosis and Treatment Center of Henan Province, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Oncology, Lymphoma Diagnosis and Treatment Center of Henan Province, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaorui","family":"Fu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Lymphoma Diagnosis and Treatment Center of Henan Province, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinhua","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Lymphoma Diagnosis and Treatment Center of Henan Province, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingjing","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Lymphoma Diagnosis and Treatment Center of Henan Province, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenchang","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Oncology, Lymphoma Diagnosis and Treatment Center of Henan Province, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xudong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Lymphoma Diagnosis and Treatment Center of Henan Province, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Lymphoma Diagnosis and Treatment Center of Henan Province, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feifei","family":"Nan","sequence":"additional","affiliation":[{"name":"Department of Oncology, Lymphoma Diagnosis and Treatment Center of Henan Province, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaqin","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Oncology, Lymphoma Diagnosis and Treatment Center of Henan Province, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhaoming","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Oncology, Lymphoma Diagnosis and Treatment Center of Henan Province, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengyuan","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken H.","family":"Young","sequence":"additional","affiliation":[{"name":"Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingzhi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Lymphoma Diagnosis and Treatment Center of Henan Province, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2018,1,2]]},"reference":[{"key":"1","first-page":"115","article-title":"CA: a cancer journal for clinicians","volume":"66","author":"He","year":"2015","journal-title":"CA Cancer J Clin"},{"key":"2","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/S0140-6736(12)60605-9","article-title":"Non-Hodgkin lymphoma","volume":"380","author":"Hancock","year":"2012","journal-title":"Lancet"},{"key":"3","doi-asserted-by":"crossref","first-page":"6075","DOI":"10.2147\/DDDT.S97235","article-title":"Apatinib for molecular targeted therapy in tumor","volume":"9","author":"Zhang","year":"2015","journal-title":"Drug Des Devel Ther"},{"key":"4","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.canlet.2016.01.014","article-title":"Apatinib: A novel receptor tyrosine kinase inhibitor for the treatment of gastric cancer","volume":"372","author":"Generali","year":"2016","journal-title":"Cancer letters"},{"key":"5","doi-asserted-by":"publisher","first-page":"17220","DOI":"10.18632\/oncotarget.7948","article-title":"Apatinib inhibits VEGF signaling and promotes apoptosis in intrahepatic cholangiocarcinoma","volume":"7","author":"Kuang","year":"2016","journal-title":"Oncotarget"},{"key":"6","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1002\/ijc.28829","article-title":"Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer","volume":"135","author":"Wang","year":"2014","journal-title":"Int J Cancer"},{"key":"7","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.ctrv.2012.05.003","article-title":"Targeted agents in the third-\/fourth-line treatment of patients with advanced (stage III\/IV) non-small cell lung cancer (NSCLC)","volume":"39","author":"Postmus","year":"2013","journal-title":"Cancer Treat Rev"},{"key":"8","doi-asserted-by":"publisher","first-page":"42252","DOI":"10.18632\/oncotarget.15036","article-title":"Overwhelming rapid metabolic and structural response to apatinib in radioiodine refractory differentiated thyroid cancer","volume":"8","author":"Liang","year":"2017","journal-title":"Oncotarget"},{"key":"9","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0031-6997(24)01448-0","article-title":"Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation","volume":"52","author":"Molema","year":"2000","journal-title":"Pharmacol Rev"},{"key":"10","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Rogers","year":"2004","journal-title":"N Engl J Med"},{"key":"11","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Figlin","year":"2007","journal-title":"N Engl J Med"},{"key":"12","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1046\/j.1365-2141.1999.01547.x","article-title":"Angiogenic growth factors and endostatin in non-Hodgkin\u2019s lymphoma","volume":"106","author":"Martinelli","year":"1999","journal-title":"Br J Haematol"},{"key":"13","doi-asserted-by":"crossref","first-page":"3712","DOI":"10.1182\/blood.V96.12.3712","article-title":"Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: a single-institution study of 200 patients","volume":"96","author":"Joensuu","year":"2000","journal-title":"Blood"},{"key":"14","first-page":"108","article-title":"Simultaneous determination of apatinib and its four major metabolites in human plasma using liquid chromatography-tandem mass spectrometry and its application to a pharmacokinetic study","author":"Zhong","year":"2012","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"15","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1080\/10428190902856808","article-title":"A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest oncology group study S0108","volume":"50","author":"Miller","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"16","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1182\/blood-2012-04-423079","article-title":"A phase 2 trial of standard-dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab plus bevacizumab for patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: SWOG 0515","volume":"120","author":"Miller","year":"2012","journal-title":"Blood"},{"key":"17","doi-asserted-by":"crossref","first-page":"5404","DOI":"10.1200\/JCO.2008.21.1169","article-title":"Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin\u2019s Lymphoma","volume":"27","author":"Vose","year":"2009","journal-title":"J Clin Oncol"},{"key":"18","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1186\/1471-2407-10-529","article-title":"Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies","volume":"10","author":"Zuo","year":"2010","journal-title":"BMC Cancer"},{"key":"19","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1111\/j.1349-7006.2011.01939.x","article-title":"YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activityand","volume":"102","author":"Lou","year":"2011","journal-title":"Cancer science"},{"key":"20","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1200\/JCO.2015.63.5995","article-title":"Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction","volume":"34","author":"Ouyang","year":"2016","journal-title":"J Clin Oncol"},{"key":"21","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1358\/dot.2015.51.4.2320599","article-title":"Apatinib: a promising oral antiangiogenic agent in the treatment of multiple solid tumors","volume":"51","author":"Jimeno","year":"2015","journal-title":"Drugs Today (Barc)"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.23806","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,29]],"date-time":"2025-06-29T09:51:08Z","timestamp":1751190668000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.23806"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,2]]},"references-count":21,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2018,3,23]]}},"alternative-id":["23806","29662638"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.23806","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,2]]}}}